RSS   Newsletter   Contact   Advertise with us
Post Online Media

Alexion Pharmaceuticals appoints Ludwig N. Hantson as CEO

Alexion PharmaceuticalsAlexion Pharmaceuticals, a pharmaceutical company, announced that it has appointed Ludwig N. Hantson as chief executive officer and member of the board of directors.

Dr. Hantson most recently served as President and CEO of Baxalta, a spin-off as a public company from Baxter.

Article continues below

READ MORE Alexion Pharmaceuticals appoints John T. Mollen to board

Prior to his roles at Baxalta and Baxter BioScience, Dr. Hantson held several leadership roles during his decade-long tenure at Novartis from 2001-2010, including CEO of Novartis Pharma North America, CEO of Novartis Europe, and President of Novartis Pharma Canada.

Dr. Hantsone began his career at Smith & Nephew and subsequently served in increasing roles of responsibility in marketing, and research and development at Johnson & Johnson from 1988-2001.

Dr. Hantson received his Ph.D. in motor rehabilitation and physical therapy, Master’s degree in physical education, and a certification in high secondary education, all from the University of Louvain in Belgium.


 LATEST MOVES FROM Connecticut 





More inside POST
 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy